PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade) in combination with cetuximab in squamous cell carcinoma cell lines (SCC). METHODS: Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay. RESULTS: Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P < 0.042), and the activity was further significantly enhanced by the addition of cetuximab (P < 0.043). CONCLUSIONS: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.
PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade) in combination with cetuximab in squamous cell carcinoma cell lines (SCC). METHODS: Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay. RESULTS:Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P < 0.042), and the activity was further significantly enhanced by the addition of cetuximab (P < 0.043). CONCLUSIONS: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.
Authors: Melinda M Mortenson; Michael G Schlieman; Subbulakshmi Virudachalam; Richard J Bold Journal: Cancer Chemother Pharmacol Date: 2004-06-12 Impact factor: 3.333
Authors: Yi-He Ling; Leonard Liebes; Bruce Ng; Michael Buckley; Peter J Elliott; Julian Adams; Jian-Dong Jiang; Franco M Muggia; Roman Perez-Soler Journal: Mol Cancer Ther Date: 2002-08 Impact factor: 6.261
Authors: Athanassios Argiris; Austin G Duffy; Shivaani Kummar; Nicole L Simone; Yoshio Arai; Seungwon W Kim; Susan F Rudy; Vishnu R Kannabiran; Xinping Yang; Minyoung Jang; Zhong Chen; Nanette Suksta; Theresa Cooley-Zgela; Susmita G Ramanand; Aarif Ahsan; Mukesh K Nyati; John J Wright; Carter Van Waes Journal: Clin Cancer Res Date: 2011-07-12 Impact factor: 12.531
Authors: Jens Wagenblast; Daniel Hirth; Laura Thron; Christoph Arnoldner; Marc Diensthuber; Timo Stöver; Markus Hambek Journal: Oncol Lett Date: 2012-04-30 Impact factor: 2.967
Authors: Pierre Saintigny; Li Zhang; You-Hong Fan; Adel K El-Naggar; Vassiliki A Papadimitrakopoulou; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Li Mao Journal: Cancer Prev Res (Phila) Date: 2011-02
Authors: Martin Leinung; Daniel Hirth; Aykut Tahtali; Marc Diensthuber; Timo Stöver; Jens Wagenblast Journal: Oncol Lett Date: 2012-09-20 Impact factor: 2.967
Authors: Yan Zang; Sufi M Thomas; Elena T Chan; Christopher J Kirk; Maria L Freilino; Hannah M DeLancey; Jennifer R Grandis; Changyou Li; Daniel E Johnson Journal: Clin Cancer Res Date: 2012-08-28 Impact factor: 12.531
Authors: A Z Dudek; K Lesniewski-Kmak; N J Shehadeh; O N Pandey; M Franklin; R A Kratzke; E W Greeno; P Kumar Journal: Br J Cancer Date: 2009-05-05 Impact factor: 7.640